Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (1849)	10/19/2000 12:13:52 AM
From: Doc Bones	Respond to of 52153

Brief comments on earnings reports by Gabe Hoffman, biotech columnist at Real Money / The Street.Com -------------- Gabe Hoffman MEDI / IMNX reports 10/18/00 6:11 PM ET Medimmune was in line, stock basically unchanged. Immunex Leukine sales were strong, will be interesting to see if this affects Amgen's Neupogen sales when they report. Enbrel was a couple million light, stock is off about 3 points after mkt. Enormous secondary is still hanging over IMNX, was reduced from 70 million to 60 million, still equals well over $2 billion of new supply. long AMGN